Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. The Searle Co's Free Cash Flow for the
three
months ended in Mar. 2026 was ₨-433 Mil. The Searle Co's Revenue for the
three
months ended in Mar. 2026 was ₨9,734 Mil. Therefore, The Searle Co's FCF Margin % for the quarter that ended in Mar. 2026 was -4.45%.
The historical rank and industry rank for The Searle Co's FCF Margin % or its related term are showing as below:
KAR:SEARL'
s FCF Margin % Range Over the Past 10 Years
Min: -7.29 Med: -0.34 Max: 13.54
Current: -0.33
During the past 13 years, the highest FCF Margin % of The Searle Co was 13.54%. The lowest was -7.29%. And the median was -0.34%.
KAR:SEARL's FCF Margin % is ranked worse than 58.46% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.55
vs KAR:SEARL: -0.33
The Searle Co FCF Margin % Related Terms
The Searle Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for The Searle Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:SEARL vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The Searle Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Searle Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The Searle Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where The Searle Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Searle Co (KAR:SEARL) has a FCF Margin % of -4.45% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on The Searle Co and its competitors. According to the industry distribution chart, The Searle Co ranks #563 out of 963 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is The Searle Co's FCF Margin % too high?
The Searle Co's current FCF Margin % is -4.45%. Based on the distribution chart, The Searle Co ranks #563 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, The Searle Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Searle Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, The Searle Co ranks #563 out of 963 companies for FCF Margin %. This places The Searle Co in the lower half of its industry. The industry median FCF Margin % is 2.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on The Searle Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Searle Co's current FCF Margin % is -4.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Searle Co stock overvalued right now?
Based on GuruFocus' analysis, The Searle Co (KAR:SEARL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨76.13, compared to a current price of ₨92.30 — trading 21.2% above its estimated fair value. The current FCF Margin % is -4.45%. The Searle Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For The Searle Co (KAR:SEARL), the current FCF Margin % is -4.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Searle Co (KAR:SEARL) Overvalued in 2026?
Based on GuruFocus' analysis, The Searle Co stock appears to be overvalued.
The current stock price of ₨92.30 is trading 21.2% above its estimated GF Value™ of ₨76.13.
GuruFocus considers The Searle Co to be Modestly Overvalued.
Key valuation signals for KAR:SEARL:
FCF Margin %: -4.45%
GF Value™: ₨76.13 vs. price of ₨92.30 (21.2% above fair value)
No single metric tells the full story. See the KAR:SEARL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
73GF Score
Get the complete analysis for KAR:SEARL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:SEARL has been successfully added to your 
